CN103372076A - Medicine for treating diseases caused by propionibacterium acnes and application of sanguisorba officinalis and/or sanguisorba officinalis extract - Google Patents
Medicine for treating diseases caused by propionibacterium acnes and application of sanguisorba officinalis and/or sanguisorba officinalis extract Download PDFInfo
- Publication number
- CN103372076A CN103372076A CN2012101196477A CN201210119647A CN103372076A CN 103372076 A CN103372076 A CN 103372076A CN 2012101196477 A CN2012101196477 A CN 2012101196477A CN 201210119647 A CN201210119647 A CN 201210119647A CN 103372076 A CN103372076 A CN 103372076A
- Authority
- CN
- China
- Prior art keywords
- radix
- extraction
- medicine
- extract
- propionibacterium acnes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 98
- 239000000284 extract Substances 0.000 title claims abstract description 93
- 229940079593 drug Drugs 0.000 title claims abstract description 49
- 241000186427 Cutibacterium acnes Species 0.000 title claims abstract description 47
- 229940055019 propionibacterium acne Drugs 0.000 title claims abstract description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 25
- 201000010099 disease Diseases 0.000 title claims abstract description 24
- 244000173853 Sanguisorba officinalis Species 0.000 title abstract description 12
- 235000008282 Sanguisorba officinalis Nutrition 0.000 title abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 194
- 239000000243 solution Substances 0.000 claims description 97
- 238000000605 extraction Methods 0.000 claims description 69
- 238000002360 preparation method Methods 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 31
- 239000012567 medical material Substances 0.000 claims description 27
- 238000010992 reflux Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000005325 percolation Methods 0.000 claims description 20
- -1 tincture Substances 0.000 claims description 17
- 239000008367 deionised water Substances 0.000 claims description 15
- 229910021641 deionized water Inorganic materials 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 14
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 10
- 206010000496 acne Diseases 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 229940023488 pill Drugs 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010031149 Osteitis Diseases 0.000 claims description 4
- 206010067268 Post procedural infection Diseases 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 208000018339 bone inflammation disease Diseases 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 208000008494 pericarditis Diseases 0.000 claims description 4
- 239000000829 suppository Substances 0.000 claims description 4
- 201000005060 thrombophlebitis Diseases 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 229940046011 buccal tablet Drugs 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 47
- 230000008901 benefit Effects 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 44
- 230000003385 bacteriostatic effect Effects 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 16
- 238000012372 quality testing Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000003113 dilution method Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical class OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000196123 Matteuccia Species 0.000 description 1
- 235000007899 Matteuccia struthiopteris Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000011177 media preparation Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicine for treating diseases caused by propionibacterium acnes and application of sanguisorba officinalis and/or a sanguisorba officinalis extract, wherein the medicine comprises sanguisorba officinalis and/or sanguisorba officinalis extract in effective amount for treatment. With application of the technical scheme provided by the invention, sanguisorba officinalis and/or sanguisorba officinalis extract is adopted to prepare medicines for treating diseases caused by propionibacterium acnes, and sanguisorba officinalis and/or sanguisorba officinalis extract belongs to the scope of traditional Chinese medicines, has the advantages of low adverse reaction, difficulty in drug resistance and the like in the treatment process, and has better inhibiting and killing effect to propionibacterium acnes.
Description
Technical field
The present invention relates to field of medicaments, the medicine of the disease that is caused by propionibacterium acnes in particular to a kind for the treatment of and the application of Radix Sanguisorbae and/or Radix Sangusorbae extract.
Background technology
Antibiotic use is effectively controlled many serious bacterial infection diseases, but its unreasonable use has caused the increase of Resistant strain, has reduced existing antibiotic use effectiveness.Chinese medicine is low because of its untoward reaction in treatment, be difficult for producing the advantage such as drug resistance, and is in widespread attention, and the folk prescription with antibacterial action of being made by Chinese medicine or compound preparation and Chinese medicine and western medicine compatibility agent are applied to clinical more and more, show good effect.
Acne is the chronic inflammatory disease that betides hair follicle, sebaceous gland, is mainly in the adolescence men and women.Its morbidity is relevant with factors such as hormonal readiness, abnormal cornification of pilosebaceous duct, infected by microbes.Studies show that the increasing the weight of of the generation of propionibacterium acnes (Propionibacterium acnes is abbreviated as P.acnes) and acne and inflammatory reaction thereof has clear and definite relation.
Propionibacterium acnes (P.acnes) also claim Propiobacterium, Propionibacterium, is a kind of anaerobism brevibacterium of Gram-positive, generally resides in the hair follicle and sebaceous gland of skin.Propionibacterium acnes plays the role of a nucleus in a plurality of paathogenic factors of acne, the infection such as breathing, cardiovascular, digestion, urinary system, nerve, osteoarthrosis system and eyes be can cause in addition, infective endocarditis, thrombophlebitis, osteitis, arthritis, acute suppurative pericarditis and other post-operative infection complication shown as.
The Chinese medicine Radix Sanguisorbae is the dry root of rosaceous plant Radix Sanguisorbae Sanguisorba officinalis L. or the Radix Sanguisorbae Sanguisorba officinalis L.var.longifolia (Bert.) that comes into leaves, Radix Sanguisorbae is herbaceos perennial, has another name called: Rhizoma cimicifugae simplicis, red silk ball, Herba Ophioglossi, little Radix Arnebiae (Radix Lithospermi), whip Fructus Jujubae beard, Matteuccia struthiopteri, spouting bleeding from anus grass.All there is distribution each province, China north and south, and is adaptable.The Chinese medicine Radix Sanguisorbae has the effect of convergence, hemostasis, antiinflammatory; Cure mainly the diseases such as gastrointestinal hemorrhage, enteritis, diarrhoea.Radix Sanguisorbae has good inhibitory action to Bacillus typhi, meningococcus, staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, Salmonella etc.
Have no relevant Radix Sanguisorbae and extract thereof to research report and the application of propionibacterium acnes inhibitory or killing effect.
Summary of the invention
The present invention aims to provide medicine, and the application of Radix Sanguisorbae and/or Radix Sangusorbae extract of the disease that a kind for the treatment of causes by propionibacterium acnes, easily produces untoward reaction in therapeutic process, easily produces chemical sproof technical problem with the medicine that solves Acne treatment in the prior art.
To achieve these goals, according to an aspect of the present invention, provide the medicine of the disease that a kind for the treatment of causes by propionibacterium acnes, this medicine comprises Radix Sanguisorbae and/or the Radix Sangusorbae extract for the treatment of effective dose.
Further, medicine comprises Radix Sanguisorbae and/or the Radix Sangusorbae extract of 0.1wt%-99.9wt%.
Further, infectious heart film inflammation, thrombophlebitis, osteitis, arthritis, acute suppurative pericarditis and postoperative infection complication that the disease that is caused by propionibacterium acnes comprises acne, caused by propionibacterium acnes.
Further, Radix Sangusorbae extract is prepared from by the method that decocts extraction, hot reflux extraction, percolation extraction, supersound extraction, microwave extraction.
Further, Radix Sangusorbae extract is prepared from by the following method: add medical material weight 5-10 volume extraction solvent doubly in Radix Sanguisorbae crude drug or decoction pieces, hot reflux or supersound extraction 1-2 hour, obtain for the first time extracting solution; In medicinal residues, add again Radix Sanguisorbae crude drug or decoction pieces medical material weight 5-10 volume extraction solvent doubly, hot reflux or supersound extraction 1-2 hour again, obtain for the second time extracting solution, with the extracting solution merging first time, then carry out concentration and get Radix Sangusorbae extract, wherein, extracting solvent is the ethanol of deionized water or 5%-95%.
Further, Radix Sangusorbae extract is prepared from by the following method: get Radix Sanguisorbae crude drug or decoction pieces, after expanding with water-wet, add in the percolation post, add and extract solvent 5%-95% ethanol to full, soaked 1-24 hour; Then add 5%-95% ethanol and carry out percolation and extract, keep liquid level to be higher than medical material, collect percolate to percolate without color till, then carry out concentration and get Radix Sangusorbae extract.
Further, the concentration of extraction etoh solvent is 50%-85%.
Further, the dosage form of medicine is selected from tablet, capsule, drop pill, aerosol, gel, tincture, ointment, membrane, lotion, liniment, pill, powder, solution, suspensoid, Emulsion, granule, liposome, transdermal patch, buccal tablet, suppository, lyophilized injectable powder, injection, oral liquid or paster.
According to another aspect of the present invention, provide the application in the medicine of the disease that is caused by propionibacterium acnes for the preparation for the treatment of of a kind of Radix Sanguisorbae and/or Radix Sangusorbae extract.
According to a further aspect of the invention, provide the application in the vitro inhibition propionibacterium acnes of a kind of Radix Sanguisorbae and/or Radix Sangusorbae extract.
Use technical scheme of the present invention, adopt the preparation of Radix Sanguisorbae or Radix Sangusorbae extract to treat the medicine of the disease that is caused by propionibacterium acnes, Radix Sanguisorbae or Radix Sangusorbae extract belong to the Chinese medicine category, its have in therapeutic process untoward reaction low, be difficult for producing the advantage such as drug resistance, and, Radix Sanguisorbae or Radix Sangusorbae extract to propionibacterium acnes press down to kill effect better.
The specific embodiment
Need to prove that in the situation of not conflicting, embodiment and the feature among the embodiment among the present invention can make up mutually.Describe the present invention in detail below in conjunction with embodiment.
A kind of typical embodiment according to the present invention, this treatment comprises Radix Sanguisorbae and/or the Radix Sangusorbae extract for the treatment of effective dose by the medicine of the disease that propionibacterium acnes causes.Radix Sanguisorbae or Radix Sangusorbae extract belong to the Chinese medicine category, it is natural to originate, and make its its have a low advantage of untoward reaction in therapeutic process, complicated component makes it be difficult for producing the advantages such as drug resistance, and, Radix Sanguisorbae or Radix Sangusorbae extract to propionibacterium acnes press down to kill effect better.Preferably, this medicine comprises Radix Sanguisorbae and/or the Radix Sangusorbae extract of 0.1wt%-99.9wt%.
Propionibacterium acnes is a kind of anaerobe of Gram stained positive, is a kind of cytozoicus antibacterial, belongs to the normal flora of skin, the compositions such as it can secretory protein, enzyme, lipopolysaccharide, also can stimulate body to produce antibody, all these can both become paathogenic factor, cause various diseases.Wherein, among the present invention the alleged disease that is caused by propionibacterium acnes can be acne, infectious heart film inflammation, thrombophlebitis, osteitis, arthritis, acute suppurative pericarditis or the postoperative infection complication etc. that are caused by propionibacterium acnes.
" Radix Sangusorbae extract " of the present invention can be the extract that adopts all methods extraction Radix Sanguisorbae gained of existing Chinese medicine extraction technology such as decocting extraction, hot reflux extraction, percolation extraction, supersound extraction, microwave extraction, wherein, better extracting method is that hot reflux is extracted.
A kind of typical embodiment according to the present invention, Radix Sangusorbae extract is prepared from by the following method: add the 5-10 volume extraction solvent doubly of medical material weight in Radix Sanguisorbae crude drug or the decoction pieces, hot reflux or supersound extraction 1-2 hour, emit for the first time extracting solution; In medicinal residues, add again 5-10 volume extraction solvent doubly, hot reflux or supersound extraction 1-2 hour again, emit for the second time extracting solution, with the extracting solution merging first time, get the Radix Sanguisorbae extracting solution, wherein, extracting solvent is the ethanol of deionized water or 5%-95%.With Radix Sanguisorbae extracting solution standardize solution or after weighing quantitatively, the sample that takes a morsel carries out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other Radix Sanguisorbae extracting solution carry out concentration, get Radix Sangusorbae extract, can be used for preparing folk prescription or compound preparation." Radix Sangusorbae extract " of the present invention, extracting solvent can be water, 5%～95% ethanol, or all solvents that can use of other organic solvent such as the existing Chinese medicine extraction technology such as acetone, methanol, better extraction solvent is 50%-85% ethanol.
The another kind of typical embodiment according to the present invention, Radix Sangusorbae extract is prepared from by the following method: get Radix Sanguisorbae crude drug or decoction pieces, after expanding with water-wet, add in the percolation post, add and extract solvent 5%-95% ethanol to full, soaked 1-24 hour; Then slowly stream adds 5%-95% ethanol and carries out percolation and extract, and keeps liquid level to be higher than medical material, collect percolate to percolate without color till, get the Radix Sanguisorbae extracting solution.With this Radix Sanguisorbae extracting solution mixing standardize solution or after weighing quantitatively, the sample that takes a morsel carries out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other Radix Sanguisorbae extracting solution carry out concentration, get Radix Sangusorbae extract, can be used for preparing folk prescription or compound preparation.Preferably, the extraction etoh solvent that add to be used for soaks in the above-mentioned percolation post and the extraction etoh solvent of follow-up percolation extraction are the same concentration.Radix Sangusorbae extract of the present invention can be realized by technique scheme, but be not limited to technique scheme.
Produce the advantages such as drug resistance owing to untoward reaction in Radix Sanguisorbae and/or the Radix Sangusorbae extract therapeutic process is low, difficult, and, Radix Sanguisorbae or Radix Sangusorbae extract to propionibacterium acnes press down to kill effect better, therefore, Radix Sanguisorbae and/or Radix Sangusorbae extract can be used in the medicine of the disease that is caused by propionibacterium acnes for the preparation for the treatment of, also can use aspect the vitro inhibition propionibacterium acnes.
In a kind of typical embodiment of the present invention, treatment comprises the Radix Sangusorbae extract for the treatment of effective dose by the medicine of the disease that propionibacterium acnes causes.Alternatively, also comprise pharmaceutically acceptable carrier, excipient, adjuvant or other adjuvants.Treatment can be prepared according to methods known in the art by the medicine of the disease that propionibacterium acnes causes.When being used for this purpose, if necessary, Radix Sangusorbae extract and one or more solids or liquid medicine excipient and/or adjuvant can be combined, make and can be used as the suitable administration form of human or dosage form.
Radix Sangusorbae extract of the present invention or contain its medicine can the unit dosage form administration, route of administration can be intestinal or non-intestinal, such as oral, muscle, subcutaneous, nasal cavity, oral mucosa, skin, peritoneum or rectum etc.Form of administration such as tablet, capsule, drop pill, aerosol, gel, tincture, ointment, membrane, lotion, liniment, pill, powder, solution, suspensoid, Emulsion, granule, liposome, transdermal patch, buccal tablet, suppository, lyophilized injectable powder, injection, oral liquid or paster etc.Can be ordinary preparation, slow releasing preparation, immediate release dosage form or enteric dosage form and various particulate delivery system.For the unit form of administration is made tablet, can be widely used various carrier well known in the art.Example about carrier is, for example diluent and absorbent are such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, carbamide, calcium carbonate, kaolin, microcrystalline Cellulose, aluminium silicate etc.; Wetting agent and binding agent are such as water, glycerol, Polyethylene Glycol, ethanol, propanol, starch slurry, dextrin, syrup, Mel, glucose solution, mucialga of arabic gummy, gelatine size, sodium carboxymethyl cellulose, lac, methylcellulose, potassium phosphate, polyvinylpyrrolidone etc.; Disintegrating agent, such as dry starch, alginate, agar powder, laminaran, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, Sorbitol fatty acid ester, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.; Disintegrate inhibitor, for example sucrose, glyceryl tristearate, cocoa butter, hydrogenation wet goods; Absorption enhancer, such as quaternary ammonium salt, sodium lauryl sulphate etc.; Lubricant, such as Pulvis Talci, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, Polyethylene Glycol etc.Tablet further can also be made coated tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablet and multilayer tablet.For pill is made in the administration unit, can be widely used various carrier well known in the art.Example about carrier is, for example diluent and absorbent are such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, Kaolin, Pulvis Talci etc.; Binding agent such as arabic gum, Tragacanth, gelatin, ethanol, Mel, liquid sugar, rice paste or batter etc.; Disintegrating agent is such as agar powder, dry starch, alginate, dodecyl sodium sulfate, methylcellulose, ethyl cellulose etc.For suppository is made in the administration unit, can be widely used various carrier well known in the art.Example about carrier is, such as the ester of Polyethylene Glycol, lecithin, cocoa butter, higher alcohol, higher alcohol, gelatin, semi-synthetic glyceride etc.For capsule is made in the administration unit, the effective ingredient Radix Sangusorbae extract is mixed with above-mentioned various carriers, and the mixture that will obtain thus places hard obviously capsule or soft capsule.Also the effective ingredient Radix Sangusorbae extract can be made microcapsule, be suspended in and form suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.For injection preparation is made in the administration unit, such as solution, Emulsion, lyophilized injectable powder and suspensoid, can use this area all diluent commonly used, for example, the isooctadecanol of water, ethanol, Polyethylene Glycol, 1,3-PD, ethoxylation, the isooctadecanol of polyoxy, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, to ooze injection in order preparing etc., can in injection preparation, to add an amount of sodium chloride, glucose or glycerol, in addition, can also add conventional cosolvent, buffer agent, pH adjusting agent etc.
In addition, such as needs, also can in pharmaceutical preparation, add coloring agent, antiseptic, spice, correctives, sweeting agent or other material.
The dosage of Radix Sangusorbae extract of the present invention depends on many factors, for example will prevent or treat character and the order of severity of disease, the sex of patient or animal, age, body weight and individual reaction, route of administration and administration number of times etc.Above-mentioned dosage can the single dose form or be divided into several, for example two, three or four dosage form administrations.
When being used for above-mentioned treat and/or prevent or during auxiliary treatment, the Radix Sangusorbae extract that treats and/or prevents effective dose can be used with pure form, perhaps, can accept excipient by Radix Sangusorbae extract and one or more medicines and form the pharmaceutical composition administration.Term " effective dose " refers to realize treating, prevent, alleviate and/or alleviating the dosage of disease of the present invention or disease in the experimenter.But it should be understood that the total consumption per day of medicine that the present invention contains the Radix Sangusorbae extract of effective dosage must be examined the doctor and maked decision in the medical judgment scope reliably by main.For any concrete patient, the concrete horizontal fibrous root for the treatment of effective dose is decided according to many factors, and described factor comprises the order of severity of the obstacle for the treatment of and this obstacle; Patient's age, body weight, general health situation, sex and diet; The administration time of the medicine that adopts, route of administration and excretion rate; The treatment persistent period; The medicine that uses simultaneously; And the known similar factor of medical field.For example, the way of this area is, the dosage of medicine increases dosage, until obtain required effect from being lower than for obtaining the level that required therapeutic effect requires gradually.
According to a further aspect in the invention, provide the application in the vitro inhibition propionibacterium acnes of a kind of Radix Sanguisorbae and/or Radix Sangusorbae extract.Its application process comprises the Radix Sanguisorbae of effective dose and/or Radix Sangusorbae extract is contacted at external material with carrying propionibacterium acnes, as smear Radix Sanguisorbae and/or the Radix Sangusorbae extract of effective dose at the skin surface of suffering from acne.
Further specify the present invention below in conjunction with concrete experiment, but be not limited to the present invention.
Radix Sangusorbae extract of the present invention is tested the propionibacterium acnes inhibitory action
Bacteriostatic experiment 1
Experiment material:
1, strain and source: propionibacterium acnes Propionibacterium acnes (the P.a numbering: 10312), Chinese industrial microorganism fungus kind preservation administrative center.
2, culture medium: THIOGLYCOLLIC ACID salt fluid culture medium is purchased from National Institute for Food and Drugs Control.
3, Radix Sanguisorbae medical material: the Radix Sanguisorbae decoction pieces, available from Beijing pharmacy of Tongrentang.
4, Maxwell opacity tube: 0.5 Maxwell standard opacity tube is equivalent to 1.5 * 10
8CFU/mL is purchased from Nuo Taian Science and Technology Ltd. in Beijing.
Minimal inhibitory concentration (minimal inhibitory concentration, MIC) assay method:
Double dilution method, the detection by quantitative Radix Sanguisorbae is to the minimal inhibitory concentration (MIC) of propionibacterium acnes.
Experimental technique:
1, Radix Sanguisorbae extracting solution preparation (hot reflux extraction): accurately take by weighing 10 parts of each 10.0g of Radix Sanguisorbae pharmaceutical decocting piece, place respectively 150ml ground conical flask, each adds deionized water, 5% ethanol, 20% ethanol, 30% ethanol, 40% ethanol, 50% ethanol, 70% ethanol, 85% ethanol, 90% ethanol, each 100ml of 95% ethanol, put and add condensation reflux unit on the electric hot plate, hot reflux was extracted 1.0 hours, leached extracting solution; Medicinal residues add each 80ml of former solvent again, and hot reflux was extracted 1.0 hours, leached extracting solution, and extracted twice liquid merges, and the cooling mixing is extracting solution stock solution, measures extracting liquid volume.Get a certain amount of extraction stock solution, with former extraction solvent each extracting solution crude drug concentration all is configured to 50mg/ml, be used for measuring minimal inhibitory concentration.
2, pastille culture medium preparation: medicinal liquid (crude drug 50mg/ml) is configured to every ml with THIOGLYCOLLIC ACID salt fluid culture medium respectively and contains crude drug amount 5mg, 2.5mg, 1.25mg, 0.625mg, 0.312mg, 0.156mg, 0.078mg, 0.039mg, 0.020mg totally 9 drug level (label 1-9 pipe), control tube label 10: for not adding the positive growth control pipe of medicinal liquid.Two groups of packing, A organizes every pipe total amount 4.8ml (adding the bacterium test group), and B organizes every pipe total amount 5.0ml (not adding the bacterium matched group), the autoclaving sterilization.
3, bacteriostatic experiment:
(1) test bacterium solution preparation: get the activated cultured propionibacterium acnes bacterium of the bacterium liquid that increases, centrifugal with aseptic centrifuge tube, bacterial sediment is diluted to 0.5 Maxwell than turbid unit with physiological saline solution, and namely about 10
8CFU/ml.
(2) Accelerated Life bacterium liquid: get the rear pastille culture medium of sterilization (1-10 number pipe of A deck label), with aseptic pipet Accelerated Life bacterium liquid 0.20ml, shake up.
(3) cultivate: A group and B group are put into simultaneously 37 ℃ of anaerobism and were cultivated 3-5 days.
(4) contrast: strain contrast is not for containing the culture medium Accelerated Life bacterium (A organizes pipe No. 10) of medicine, and the medicine contrast is the medicinal liquid of Accelerated Life bacterium (the B group is managed for 1-10 number) not.
(5) result judges: the medicinal liquid of Accelerated Life bacterium is not as contrast to organize identical diluted concentration with B, and turbidity is index, and naked-eye observation A organizes each pipe asepsis growth, judges minimal inhibitory concentration (MIC).
Experimental result: B organizes not all long bacterium of Accelerated Life bacterium, does with the comparison of concentration medicine turbidity, and A group Accelerated Life bacterium is organized with B and compares.The results are shown in Table 1-table 10, minimal inhibitory concentration the results are shown in Table 11 and table 12.
Table 1 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 2 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 3 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 4 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression; "-+" represent that long bacterium amount is few.
Table 5 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression; "-+" represent that long bacterium amount is few.
Table 6 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 7 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 8 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression;
Table 9 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 10 Accelerated Life bacterium sample detection result
Annotate: "-" expression does not have long bacterium; The long bacterium of "+" expression.
Table 11 water bath reflux method detects Radix Sanguisorbae medical material minimal inhibitory concentration MIC
| Extract solvent | Water | 5% ethanol | 20% ethanol | 30% ethanol | 40% ethanol |
| MIC (crude drug mg/ml) | 1.25 | 1.25 | 1.25 | 1.25 | 0.625 |
Table 12 water bath reflux method detects Radix Sanguisorbae medical material minimal inhibitory concentration MIC
| Extract solvent | 50% ethanol | 70% ethanol | 85% ethanol | 90% ethanol | 95% ethanol |
| MIC (crude drug mg/ml) | 0.312 | 0.312 | 0.312 | 0.625 | 0.625 |
Bacteriostatic experiment 2: except the Radix Sanguisorbae extracting method, all the other methods are with bacteriostatic experiment 1.
Supersound extraction: get the Radix Sanguisorbae pharmaceutical decocting piece, pulverize, accurately take by weighing 8 parts of each 10.0g, place respectively 150ml ground conical flask, each add deionized water, 5% ethanol, 25% ethanol, 45% ethanol, 50% ethanol, 65% ethanol each, 85% ethanol, each 80ml of 95% ethanol, the tool plug, supersound extraction 1.0 hours leaches extracting solution; Medicinal residues add each 70ml of former solvent again, and supersound extraction is 1.0 hours again, leaches extracting solution, and extracted twice liquid merges, and mixing is extracting solution stock solution, measure extracting liquid volume.Get a certain amount of extraction stock solution, with former extraction solvent extracting solution crude drug concentration all is configured to 50mg/ml, be used for measuring minimal inhibitory concentration.Measurement result sees Table 13.
Table 13 ultrasonic extraction detects Radix Sanguisorbae medical material minimal inhibitory concentration MIC
Data by table 13 can find out that when the extraction solvent was 50%-85% ethanol, the fungistatic effect of its extract was best.
Bacteriostatic experiment 3: except the Radix Sanguisorbae extracting method, all the other methods are with bacteriostatic experiment 1.
Percolation extracts: get the Radix Sanguisorbae pharmaceutical decocting piece, pulverize, accurately take by weighing 8 parts of each 20.0g, use first the deionized water moistening, it is agglomerating that medical material after moistening is held, loose after decontroling.Then the medicated powder after moistening is poured in the percolator equably, avoided degree of tightness irregular; Lid layer filter paper presses bottle cap on the medicated powder, in case medicated powder is routed up, yield is extracted in impact; Percolator lower end piston is opened, and adds respectively to extract solvent deionized water, 5% ethanol, 35% ethanol, 50% ethanol, 55% ethanol, 75% ethanol, 85% ethanol, 95% ethanol to full, discharges bubble; Piston was closed 4 hours, soak medicated powder, open again percolation; Keep liquid level to be higher than medicated powder, percolation slowly is till the percolate very slight color.Collect percolate, mixing, surveying record percolate cumulative volume is for extracting stock solution.Get a certain amount of extraction stock solution, with former extraction solvent extracting solution crude drug concentration all is configured to 50mg/ml, be used for measuring minimal inhibitory concentration, measurement result sees Table 14.
Table 14 permeating extraction detects Radix Sanguisorbae medical material minimal inhibitory concentration MIC
Further specify preparation method and the beneficial effect of Radix Sangusorbae extract of the present invention below in conjunction with embodiment.
Embodiment 1
Get Radix Sanguisorbae crude drug decoction pieces, the 10 volumes deionized water doubly that adds medical material weight, hot reflux was extracted 1 hour, emit for the first time extracting solution, medicinal residues add 7.5 volumes deionized water doubly again, and hot reflux was extracted 1 hour again, emit for the second time extracting solution, with the first time extracting solution merge, after extracted twice liquid was merged standardize solution or weighs quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 1.25mg/ml.
Embodiment 2
Get Radix Sanguisorbae crude drug decoction pieces, the 9 volumes deionized water doubly that adds medical material weight, hot reflux was extracted 1.5 hours, emit for the first time extracting solution, medicinal residues add 8 volumes deionized water doubly again, and hot reflux was extracted 1 hour again, emit for the second time extracting solution, with the first time extracting solution merge, after extracted twice liquid was merged standardize solution or weighs quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 1.25mg/ml.
Embodiment 3
Get Radix Sanguisorbae crude drug decoction pieces, the 8 volumes deionized water doubly that adds medical material weight, supersound extraction 2 hours, emit for the first time extracting solution, medicinal residues add 6 volumes deionized water doubly again, and supersound extraction is 1 hour again, emit for the second time extracting solution, with the first time extracting solution merge, after extracted twice liquid was merged standardize solution or weighs quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 1.25mg/ml.
Embodiment 4
Get Radix Sanguisorbae crude drug decoction pieces, 9 volumes, 50% ethanol doubly that adds medical material weight, hot reflux was extracted 2 hours, emit for the first time extracting solution, medicinal residues add 5 volumes, 50% ethanol doubly again, and hot reflux was extracted 1.5 hours again, emit for the second time extracting solution, with the first time extracting solution merge, after extracted twice liquid was merged standardize solution or weighs quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 5
Get Radix Sanguisorbae crude drug decoction pieces, 8 volumes, 60% ethanol doubly that adds medical material weight, hot reflux was extracted 2 hours, emit for the first time extracting solution, medicinal residues add 6 volumes, 60% ethanol doubly again, and hot reflux was extracted 2 hours again, emit for the second time extracting solution, with the first time extracting solution merge, after extracted twice liquid was merged standardize solution or weighs quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 6
Get Radix Sanguisorbae crude drug decoction pieces, 7 volumes, 70% ethanol doubly that adds medical material weight, hot reflux was extracted 1 hour, emit for the first time extracting solution, medicinal residues add 7 volumes, 70% ethanol doubly again, and hot reflux was extracted 1 hour again, emit for the second time extracting solution, with the first time extracting solution merge, after extracted twice liquid was merged standardize solution or weighs quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 7
Get the Radix Sanguisorbae crude drug, pulverize, 8.5 volumes, 40% ethanol doubly that adds medical material weight, supersound extraction 2 hours is emitted for the first time extracting solution, medicinal residues add 7.5 volumes, 40% ethanol doubly again, supersound extraction is 2 hours again, emits for the second time extracting solution, with the extracting solution merging first time, after extracted twice liquid merged standardize solution or weigh quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.625mg/ml.
Embodiment 8
Get the Radix Sanguisorbae crude drug, pulverize, 8 volumes, 55% ethanol doubly that adds medical material weight, supersound extraction 1 hour is emitted for the first time extracting solution, medicinal residues add 7 volumes, 55% ethanol doubly again, supersound extraction is 1 hour again, emits for the second time extracting solution, with the extracting solution merging first time, after extracted twice liquid merged standardize solution or weigh quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 9
Get the Radix Sanguisorbae crude drug, pulverize, 10 volumes, 70% ethanol doubly that adds medical material weight, supersound extraction 2 hours is emitted for the first time extracting solution, medicinal residues add 6.5 volumes, 70% ethanol doubly again, supersound extraction is 1 hour again, emits for the second time extracting solution, with the extracting solution merging first time, after extracted twice liquid merged standardize solution or weigh quantitatively, the sample that takes a morsel carried out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 10
Get the Radix Sanguisorbae crude drug, pulverize, after expanding with water-wet, add in the percolation post (or percolator), add and extract solvent 60% ethanol to full, soaked 10 hours, slowly stream adds 50% ethanol and carries out percolation and extract again, and the maintenance liquid level is higher than medical material.To percolate substantially without till the color, with all percolate mixing standardize solution or after weighing quantitatively, the sample that takes a morsel carries out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other percolates carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 11
Get the Radix Sanguisorbae crude drug, pulverize, after expanding with water-wet, add in the percolation post (or percolator), add and extract solvent 70% ethanol to full, soaked 16 hours, slowly stream adds 60% ethanol and carries out percolation and extract again, and the maintenance liquid level is higher than medical material.To percolate substantially without till the color, with all percolate mixing standardize solution or after weighing quantitatively, the sample that takes a morsel carries out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other percolates carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 12
Get the Radix Sanguisorbae crude drug, pulverize, after expanding with water-wet, add in the percolation post (or percolator), add and extract solvent 80% ethanol to full, soaked 20 hours, slowly stream adds 80% ethanol and carries out percolation and extract again, and the maintenance liquid level is higher than medical material.To percolate substantially without till the color, with all percolate mixing standardize solution or after weighing quantitatively, the sample that takes a morsel carries out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other percolates carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 0.312mg/ml.
Embodiment 13
Get Radix Sanguisorbae crude drug decoction pieces, add medical material weight 10 volumes deionized water doubly, soaked 1 hour, decoct with stainless-steel pan, keep little and boiled 1 hour, leach extracting solution.Medicinal residues are added 7 volumes deionized water doubly again, again decoct, keep little and boiled 1 hour, leach secondary raffinate.With extracted twice liquid merge, mixing, standardize solution or weigh quantitatively after, the sample that takes a morsel carries out the quality testings such as content, extraction ratio, minimal inhibitory concentration.All the other extracting solution carry out concentration, get the Radix Sangusorbae extract concentrated solution, for the preparation of folk prescription or compound preparation.Detect crude drug minimal inhibitory concentration (MIC) by the double dilution method of describing in the bacteriostatic test of the present invention and be 1.25mg/ml.
Can be found out that by above-mentioned experimental result Radix Sangusorbae extract has good inhibitory or killing effect to propionibacterium acnes.And, the common external material that can present better bacteriostasis, its bacteriostasis in vivo is also better, the drug provision of the disease that this just causes for the preparation Acne treatment and by propionibacterium acnes a brand-new direction.And because Radix Sanguisorbae and extract thereof are Chinese medicine, it is few that it has a untoward reaction, the advantage such as be difficult for developing immunity to drugs, and this is undoubtedly the Gospel of vast patients with acne.
Because Radix Sangusorbae extract has good inhibitory or killing effect to propionibacterium acnes, and Radix Sangusorbae extract is simply to extract from Radix Sanguisorbae, so, must comprise in the Radix Sanguisorbae and press down the active substance that kills propionibacterium acnes in the Radix Sangusorbae extract, so Radix Sanguisorbae has inhibitory or killing effect to propionibacterium acnes.
The above is the preferred embodiments of the present invention only, is not limited to the present invention, and for a person skilled in the art, the present invention can have various modifications and variations.Within the spirit and principles in the present invention all, any modification of doing, be equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. the medicine of the disease that caused by propionibacterium acnes of a treatment is characterized in that described medicine comprises Radix Sanguisorbae and/or the Radix Sangusorbae extract for the treatment of effective dose.
2. medicine according to claim 1 is characterized in that, described medicine comprises Radix Sanguisorbae and/or the Radix Sangusorbae extract of 0.1wt%-99.9wt%.
3. medicine according to claim 1, it is characterized in that infectious heart film inflammation, thrombophlebitis, osteitis, arthritis, acute suppurative pericarditis and postoperative infection complication that the described disease that is caused by propionibacterium acnes comprises acne, caused by propionibacterium acnes.
4. medicine according to claim 1 is characterized in that, described Radix Sangusorbae extract is prepared from by the method that decocts extraction, hot reflux extraction, percolation extraction, supersound extraction, microwave extraction.
5. medicine according to claim 4, it is characterized in that, described Radix Sangusorbae extract is prepared from by the following method: add medical material weight 5-10 volume extraction solvent doubly in Radix Sanguisorbae crude drug or decoction pieces, hot reflux or supersound extraction 1-2 hour, obtain for the first time extracting solution;
In medicinal residues, add again described Radix Sanguisorbae crude drug or decoction pieces medical material weight 5-10 volume described extraction solvent doubly, hot reflux or supersound extraction 1-2 hour again, obtain for the second time extracting solution, with the described extracting solution merging first time, then carry out concentration and get described Radix Sangusorbae extract, wherein, the described extraction solvent ethanol that is deionized water or 5%-95%.
6. medicine according to claim 4 is characterized in that, described Radix Sangusorbae extract is prepared from by the following method: get Radix Sanguisorbae crude drug or decoction pieces, after expanding with water-wet, add in the percolation post, add and extract solvent 5%-95% ethanol to full, soaked 1-24 hour;
Then add 5%-95% ethanol and carry out percolation and extract, keep liquid level to be higher than medical material, collect percolate to described percolate without color till, then carry out concentration and get described Radix Sangusorbae extract.
7. according to claim 5 or 6 described medicines, it is characterized in that the concentration of described extraction etoh solvent is 50%-85%.
8. each described medicine according to claim 1-7, it is characterized in that the dosage form of described medicine is selected from tablet, capsule, drop pill, aerosol, gel, tincture, ointment, membrane, lotion, liniment, pill, powder, solution, suspensoid, Emulsion, granule, liposome, transdermal patch, buccal tablet, suppository, lyophilized injectable powder, injection, oral liquid or paster.
9. Radix Sanguisorbae and/or the Radix Sangusorbae extract application in the medicine of the disease that is caused by propionibacterium acnes for the preparation for the treatment of.
10. Radix Sanguisorbae and/or the Radix Sangusorbae extract application in the vitro inhibition propionibacterium acnes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210119647.7A CN103372076B (en) | 2012-04-20 | 2012-04-20 | Treat the medicine of disease and the application of Radix Sanguisorbae and/or Radix Sangusorbae extract that are caused by propionibacterium acnes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210119647.7A CN103372076B (en) | 2012-04-20 | 2012-04-20 | Treat the medicine of disease and the application of Radix Sanguisorbae and/or Radix Sangusorbae extract that are caused by propionibacterium acnes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103372076A true CN103372076A (en) | 2013-10-30 |
| CN103372076B CN103372076B (en) | 2015-10-14 |
Family
ID=49458322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210119647.7A Active CN103372076B (en) | 2012-04-20 | 2012-04-20 | Treat the medicine of disease and the application of Radix Sanguisorbae and/or Radix Sangusorbae extract that are caused by propionibacterium acnes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103372076B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104707015A (en) * | 2015-04-07 | 2015-06-17 | 薛青 | Medicament for operating room sterilization |
| CN108078879A (en) * | 2017-12-11 | 2018-05-29 | 华南农业大学 | For preventing the fragrant chinaberry-Bulbus Lilii extract of the Huang of propionibacterium acnes and its application |
| KR20190003010A (en) * | 2017-06-30 | 2019-01-09 | 배재대학교 산학협력단 | A cosmetic composition containing cold water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium |
| KR20190003009A (en) * | 2017-06-30 | 2019-01-09 | 배재대학교 산학협력단 | A cosmetic composition containing hot water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1051506A (en) * | 1990-10-08 | 1991-05-22 | 刘墨森 | Preparation method of novel sanguisorba officinalis preparation |
| CN1093589A (en) * | 1993-04-14 | 1994-10-19 | 刘墨森 | A kind of medicine for the treatment of acne---acne spirit |
| CN101007093A (en) * | 2007-02-08 | 2007-08-01 | 程心怡 | Medicine composition for treating acne |
-
2012
- 2012-04-20 CN CN201210119647.7A patent/CN103372076B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1051506A (en) * | 1990-10-08 | 1991-05-22 | 刘墨森 | Preparation method of novel sanguisorba officinalis preparation |
| CN1093589A (en) * | 1993-04-14 | 1994-10-19 | 刘墨森 | A kind of medicine for the treatment of acne---acne spirit |
| CN101007093A (en) * | 2007-02-08 | 2007-08-01 | 程心怡 | Medicine composition for treating acne |
Non-Patent Citations (2)
| Title |
|---|
| 周祯祥等: "《新编皮肤病验方荟萃》", 31 July 2003, 广东世界图书出版公司 * |
| 贾红慧等: "复方地榆解毒酒的药理作用", 《华西药学杂志》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104707015A (en) * | 2015-04-07 | 2015-06-17 | 薛青 | Medicament for operating room sterilization |
| KR20190003010A (en) * | 2017-06-30 | 2019-01-09 | 배재대학교 산학협력단 | A cosmetic composition containing cold water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium |
| KR20190003009A (en) * | 2017-06-30 | 2019-01-09 | 배재대학교 산학협력단 | A cosmetic composition containing hot water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium |
| KR102133074B1 (en) * | 2017-06-30 | 2020-07-10 | 배재대학교 산학협력단 | A cosmetic composition containing cold water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium |
| KR102132514B1 (en) * | 2017-06-30 | 2020-08-05 | 배재대학교 산학협력단 | A cosmetic composition containing hot water extract or its ethyl acetate fraction from Sanguisorba officinalis having specific anti-microbial activity against acne-inducing bacterium |
| CN108078879A (en) * | 2017-12-11 | 2018-05-29 | 华南农业大学 | For preventing the fragrant chinaberry-Bulbus Lilii extract of the Huang of propionibacterium acnes and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103372076B (en) | 2015-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101259172B (en) | Chinese medicinal composition for treating acne, preparation and application thereof | |
| US20110059124A1 (en) | The quality control method and application of a kind of ganoderma lucidum spore oil fat emulsion | |
| CN101862351B (en) | Application of active parts of nutgall in preparing medicine for resisting ulcerative colitis | |
| CN103372076B (en) | Treat the medicine of disease and the application of Radix Sanguisorbae and/or Radix Sangusorbae extract that are caused by propionibacterium acnes | |
| CN101664446A (en) | Relinging extractum and preparation method and application | |
| CN105193876A (en) | Purslane extract and preparation method thereof | |
| CN102824417B (en) | New method for treating helicobacter pylori related diseases | |
| CN101732669A (en) | Traditional Chinese medicine used for treating gynecologic inflammation, preparation method and application thereof | |
| CN101890114A (en) | Li nation medicament extract and composition with bacteriostatic, anti-inflammatory and hemostasis effects and preparation method thereof | |
| CN101244243B (en) | Pharmaceutical combination for treating gastritis, preparation method and application thereof | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN104546923B (en) | A kind of Polyhachis vicina Roger extract and its extracting method and application | |
| CN107184911A (en) | One kind is used to prevent cervical carcinoma and treatment papillomavirus（HPV）Infection and the product and preparation method of colpitis | |
| CN104586831A (en) | Application of high-content salvianolic acid B to prepare medicines for resisting cervical carcinoma and preparation method thereof | |
| CN111419829B (en) | Application of honokiol in inhibiting Streptococcus suis or its biofilm | |
| CN103432049B (en) | Composition with deodorization function | |
| CN106344663A (en) | Preparation method of Jin Ying Huang Gui injection | |
| CN104856986A (en) | New application of 5-hydroxymethyl-2-furaldehyde (5-HMF) in preparation of anti-liver fibrosis medicine | |
| CN104367633A (en) | Medicine combination with antibacterial and synergically-antibacterial effects, and preparation method and application | |
| CN101461904A (en) | Method for testing Chinese medicinal composition for treating painful swelling of throat and constipation | |
| CN101461903A (en) | Chinese medicinal composition for treating painful swelling of throat and constipation, and preparation method thereof | |
| WO2017020279A1 (en) | Uses of composition comprising polygonum capitatum and coptis roots in preparation of drugs for resisting against helicobacter pylori | |
| WO2017020861A1 (en) | Application of polygonum capitatum composition in resisting helicobacter pylori | |
| CN110227094B (en) | Application of albizia julibrissin aqueous extract in preparing external medicine for preventing and treating gynecological inflammatory diseases | |
| CN109125427B (en) | Penyanjing suppository and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |